Cosentyx (secukinumab) is a medication used to treat psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, its safety for pregnant women is not yet fully established. The drug is classified as a pregnancy category B medication, which means that animal studies have not shown any adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women [1].

A study published in the British Journal of Dermatology analyzed the outcomes of 10 pregnancies in women who were exposed to secukinumab during pregnancy. The study concluded that there were no major congenital malformations, but the sample size was too small to draw definitive conclusions [2].

Another study published in the Journal of the European Academy of Dermatology and Venereology analyzed the outcomes of 25 pregnancies in women who were exposed to secukinumab during pregnancy. The study concluded that secukinumab does not seem to increase the risk of adverse pregnancy outcomes, but further studies are needed to confirm these findings [3].

In summary, while the available studies suggest that secukinumab may not pose a significant risk to pregnant women, the sample sizes are too small to draw definitive conclusions. Therefore, pregnant women should consult with their healthcare provider before taking Cosentyx or any other medication during pregnancy.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://onlinelibrary.wiley.com/doi/full/10.1111/bjd.16901
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7874874/